I doubt they can lay dormant. They need to pay the interest plus they need to pursue the business. If you can't get a good investor when you're demonstrating progress and doing tests with the diamonds, you're surely not going to get one when the diamonds are cold and the on-ground equipment has cobwebs.
It's all too neatly wrapped up in timelines: interest payments starting, cash running out, annual reports published. The best lie dormant is that they sell the Polish business to related interests (like relatives) or give it in lieu of payment to the loaner (again, possibly relatives) and then wind up the rest of the business. They could leave the IP sitting in their control waiting for the moment to start again. But as for us it's either this October or it's over.
- Forums
- ASX - By Stock
- SAS
- News & Media
News & Media, page-2780
-
- There are more pages in this discussion • 450 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SAS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online